Učestalost sinkronih i metakronih neoplazija kod bolesnika s neuroendokrinim tumorom

master's thesis

• Title (english): Frequency of synchronous and metachronous neoplasia in patients with neuroendocrine tumors
• Author: Andrea Racetin
• Mentor: Borislav Belev (mentor)
• Committee member: Stjepko Pleština (predsjednik povjerenstva)
• Committee member: Ivan Bilić (član povjerenstva)
• Committee member: Borislav Belev (član povjerenstva)
• Granter: University of Zagreb; School of Medicine; (Department of Pathophysiology); Zagreb
• Defense date and country: 2022-07-15, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Pathophysiology

Abstract

Neuroendokrini tumori (NET) su tumori koji nastaju iz neuroendokrinih stanica koje čine
tzv. difuzni neuroendokrini sustav smješten u sluznici različitih organa. Najčešće su
lokalizirani u probavnom i bronhopulmonalnom sustavu te se češće pojavljuju
sporadično.
NET-ovi se povezuju s povećanom učestalošću razvoja drugih primarnih tumora (eng.
second primary malignancy ili SPM) koji se s obzirom na vrijeme nastanka mogu
podijeliti u sinkrone ili metakrone. Sinkroni tumori su oni koji nastaju unutar 6 mjeseci od
dijagnoze NET-a, a metakroni oni koji nastaju > 6 mjeseci prije ili nakon dijagnoze NETa.
U ovom radu pretražili smo arhivu Kliničkog bolničkog centra Zagreb u razdoblju od
2000. do 2021. godine i zabilježili sve bolesnike s NET-om. Analizom dokumentacije
pronašli smo 201 bolesnika s NET-om. Pronađena su 41 dodatna tumora kod 37 (od
ukupno 201) bolesnika s NET-om. U 12 (29.3%) slučajeva radilo se o sinkronim, a u 29
(70.7%) slučajeva o metakronim neoplazijama. Najzastupljenije su bile neoplazije
probavnog sustava (21 slučaj, 51.2%) i mokraćno – spolnog sustava (9 slučajeva,
21.9%). Zaključno, u skupini od 201 bolesnika s NET-om pronađena je prevalencija
sinkronih i metakronih tumora od 17.9%, što ukazuje na to da prisutnost dodatnih
primarnih tumora kod bolesnika s NET-om nije rijetkost i to treba imati u vidu tijekom
dijagnostike, terapije i praćenja bolesnika.

Abstract (english)

Neuroendocrine tumors (NET) are tumors arising from neuroendocrine cells that
form so-called diffuse neuroendocrine system located in the mucosa of various
organs. They are mostly localized in the digestive and bronchopulmonary tracts and
more often appear sporadically. NETs are associated with an increased incidence of
developing other primary tumors (second primary malignancy or SPM), which can be
divided, depending on the time of onset, into synchronous or metachronous. By
definition, synchronous tumors develop within 6 months of NET diagnosis and
metachronous tumors are those that arise > 6 months before or after NET diagnosis.
In this thesis, we analyzed the archives of University Hospital Centre Zagreb in the
period from 2000. to 2021., and recorded all patients with NET diagnosis. By
analyzing the documentation, 201 patients with NET were found. Also, 41 second
primary tumors were found in 37 (out of a total of 201) patients with NET. In 12
(29.3%) cases they were synchronous and in 29 (70.7%) cases metachronous. The
most common localization of SPM were digestive (21 cases, 51.2%) and urogenital
system (9 cases, 21.9%). To conclude, in a group of 201 patients with NET, the
prevalence of synchronous and metachronous tumors was 17.9%, which indicates
that the presence of SPM in patients with NET is not rare and should be taken into
consideration during diagnosis, therapy and follow up.

• Keywords: neuroendokrini tumori; drugi primarni tumori; sinkroni tumori; metakroni tumori
• Keywords (english): neuroendocrine tumors; second primary malignancy; synchronous tumors; metachronous tumors
• Language: croatian
• URN:NBN: urn:nbn:hr:105:765661
• Study programme: Title: Medicine; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access; Embargo expiration date: 2023-10-01
• Created on: 2023-01-02 09:45:42